MGMT and glioblastoma: Molinaro et al. recently reported a series of 478 newly diagnosed IDH-wildtype glioblastomas showing that both maximal resection of contrast-enhancing and non-contrast-enhancing parts of the tumor may impact overall survival, regardless of the MGMT promoter methylation status [3].